The accelerating demand for faster, more efficient drug development has brought digital predictive tools into sharper focus. At the FDD Conclave 2025, Merck Lifescience hosted a partner session on Day 1 titled ‘mPredict: Accelerate your drug development journey’.
The session was led by Dr Pratik Kakade, Technical Application Expert at Merck Lifescience, and introduced attendees to one of the company’s latest digital offerings. The session introduced attendees to mPredict, a digital tool designed to transform how pharma companies approach formulation and preclinical development.
By integrating datadriven intelligence into early formulation workflows, mPredict promises a more streamlined and reliable path from molecule to market. One of the core advantages of mPredict lies in its ability to recommend promising API processing strategies quickly and with high accuracy, informed Dr Kakade.
The platform is significantly faster than both random digital screening methods and traditional experimental screening, reportedly reducing screening time by up to 96 per cent. This time-saving potential could be a game changer for formulators aiming to meet aggressive development timelines without compromising on quality.
He pointed out that beyond speed, the tool offers superior accuracy. mPredict has demonstrated results that are twice as reliable and accurate compared to current industry-standard alternatives. Its predictive capability supports formulators in identifying the most effective processing routes in development, ultimately reducing risk and resource expenditure across the product lifecycle.
Through this session, Dr Kakade emphasised Merck’s commitment to enabling smarter, data-driven pharma innovation.